Related Experiment Videos
High-dose intravenous melphalan for plasma-cell leukaemia and myeloma
Lancet (London, England)
|October 8, 1983
Abstract:
1 previously untreated patient with plasma-cell leukaemia and 8 patients with myeloma (4 previously untreated) were treated with high-dose melphalan 100-140 mg/m2 iv. All responded to treatment. 3 of the 5 previously untreated patients achieved biochemical and bone-marrow complete remissions.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Studies on the Clonogenicity of Human Myeloma Cells in vitro.
Leukemia & lymphoma·2016
Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site evaluation.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2001
The changing therapeutic landscape of small-cell lung cancer.
Lancet (London, England)·2026
Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.
Lancet (London, England)·2026
Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.
Lancet (London, England)·2026
Immune Checkpoint Inhibitor Myocarditis and Myotoxicity.
Circulation·2026
Therapeutic efficacy of naloxone hydrochloride combined with hemoperfusion in toxic acute renal failure via the oxidative stress/Nrf2 pathway.
Pakistan journal of pharmaceutical sciences·2026
Machine learning prognostic model and drug survival analysis for lung adenocarcinoma in the context of radiotherapy.
Pakistan journal of pharmaceutical sciences·2026
Robotic versus laparoscopic right hemicolectomy: Does the approach matter?
Journal of minimal access surgery·2026